Osamu Asano
Overview
Explore the profile of Osamu Asano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaburagi Y, Kira K, Yahata K, Iso K, Sato Y, Matsuura F, et al.
Org Lett
. 2024 Jan;
26(14):2837-2842.
PMID: 38252895
E7130 is a novel drug candidate with an exceedingly complex chemical structure of the halichondrin class, discovered by a total synthesis approach through joint research between the Kishi group at...
2.
Ito K, Yamaguchi M, Semba T, Tabata K, Tamura M, Aoyama M, et al.
Mol Cancer Ther
. 2023 Oct;
23(2):235-247.
PMID: 37816248
E7130 is a novel anticancer agent created from total synthetic study of the natural compound norhalichondrin B. In addition to inhibiting microtubule dynamics, E7130 also ameliorates tumor-promoting aspects of the...
3.
Doi T, Matsubara N, Naito Y, Kuboki Y, Harano K, Ono M, et al.
Cancer
. 2023 Apr;
129(15):2348-2359.
PMID: 37080942
Background: E7130 is a novel anticancer agent created from a total synthetic study of norhalichondrin B. The authors report the E7130 dose-escalation part of a first-in-human study of patients with...
4.
Kawano S, Ito K, Yahata K, Kira K, Abe T, Akagi T, et al.
Sci Rep
. 2019 Jun;
9(1):8656.
PMID: 31209263
Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine...
5.
Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, et al.
Cancer Sci
. 2017 Sep;
108(11):2273-2280.
PMID: 28869796
We previously reported that eribulin mesylate (eribulin), a tubulin-binding drug (TBD), could remodel tumor vasculature (i.e. increase tumor vessels and perfusion) in human breast cancer xenograft models. However, the role...
6.
Ishii N, Wakita H, Miyazaki K, Takase Y, Asano O, Kusano K, et al.
Nihon Yakurigaku Zasshi
. 2014 Oct;
144(4):154-9.
PMID: 25312283
No abstract available.
7.
Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, et al.
J Pharmacol Exp Ther
. 2013 May;
346(1):105-12.
PMID: 23674603
Phosphodiesterase (PDE) 4 inhibition is a well-known anti-inflammatory mechanism, but the development of PDE4 inhibitors has been hampered by side effects such as nausea and emesis. Local delivery of a...
8.
Kurakake M, Takao J, Asano O, Tanimoto H, Komaki T
J Food Sci
. 2011 May;
76(2):C231-5.
PMID: 21535740
Arabinoxylans, which are comprised of a xylan backbone to which are attached glycosyl units that are primarily L-arabinofuranosyl units, are ubiquitous among plant species where it is a constituent of...
9.
Yasuda N, Nagakura T, Inoue T, Yamazaki K, Katsutani N, Takenaka O, et al.
Eur J Pharmacol
. 2006 Sep;
548(1-3):181-7.
PMID: 16973152
Dipeptidyl peptidase IV (DPP-IV) inhibitors are expected to become a useful new class of anti-diabetic agent. The aim of the present study is to characterize the in vitro and in...
10.
Yasuda N, Inoue T, Horizoe T, Nagata K, Minami H, Kawata T, et al.
Eur J Pharmacol
. 2003 Jan;
459(2-3):159-66.
PMID: 12524141
The adenosine receptor subtype mediating glucose production by glycogenolysis and gluconeogenesis was studied in primary cultured rat hepatocytes. Adenosine and adenosine agonists caused cyclic AMP accumulation in rat hepatocytes. The...